A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes and Hypertension.
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Pioglitazone; Pioglitazone/azilsartan
- Indications Hypertension in diabetes; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 13 Nov 2007 Status changed from recruiting to discontinued. An improvement in pharmaceutical formulation is needed for this combination.
- 04 Nov 2006 New trial record.